Abstracts tagged "interstitial lung disease"

Abstract Number: 1335 • ACR Convergence 2025
Chest x-Ray and pulmonary function tests are not sensitive for screening intertitial lung disease in reumatoid arthritis
Jesús Loarce¹, Alonso Sebastián González Montes², SONIA JIMENEZ BARRIOS³, Mauro Ferre-Sanfrancisco⁴, Verónica García García⁵ and Javier Bachiller⁶, ¹Ramón y Cajal University Hospital, Madrid, Spain, ²Ramón y Cajal university hospital, Madrid, Madrid, Spain, ³Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁴Department of Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, Madrid, Madrid, Spain, ⁵Ramón y Cajal University Hospital, MADRID, Spain, ⁶Hospital Ramon y Cajal, Madrid, Madrid, Spain
Background/Purpose: Interstitial lung disease (ILD) is a frequent and severe complication of rheumatoid arthritis (RA). Although early diagnosis and screening of ILD in RA patients…
Abstract Number: 1161 • ACR Convergence 2025
Comparative efficacy, safety and tolerability of antifibrotic therapies across systemic autoimmune diseases
Javier Narváez¹, Orfa Barrios², Pol Maymó-Paituvi³, JUAN JOSE ALEGRE SANCHO⁴, Ivan Castellví⁵, Vanesa Vicens Zygmunt⁶, Guadalupe Bermudo⁷, Laia De Daniel Bisbe³, Martí Aguilar-Coll⁸, Montserrat Roig Kim³, Joan Miquel Nolla³ and Maria Molina-Molina⁷, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology. Hospital Nacional Arzobispo Loayza, Lima, Peru, ³Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁴Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, ⁵Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, barcelona, Spain, ⁶Interstitial Lung Disease Unit. Department of Pneumology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷Interstitial Lung Disease Unit. Department of Pneumology. Hospital Universitario de Bellvitge., Barcelona, Spain, ⁸Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To evaluate the efficacy, safety, and tolerability of the antifibrotic agents nintedanib and pirfenidone in the treatment of interstitial lung disease (ILD) associated with…
Abstract Number: 0773 • ACR Convergence 2025
Clinical Significance of Anti-MDA5 Epitope Antibodies as Prognostic Indicators for Interstitial Lung Disease With or Without Dermatomyositis
Tsuneo Sasai¹, Ran Nakashima², Motohiro Nonaka³, Norimichi Nomura⁴, Atsubumi Ogawa¹, Yasuhiro Nohda¹, Mirei Shirakashi², Ryosuke Hiwa¹, Hideaki Tsuji¹, Hajime Yoshifuji², Shogo Matsuda⁵, Masao Katsushima⁶, Michinori Ishitoku⁷, Yusuke Yoshida⁷, Yasuyuki Todoroki⁸, Satoshi Kubo⁹, Tomohiro Handa¹⁰, Hiromi Tomioka¹¹, Ryo Tachikawa¹², Keisuke Tomii¹², Kiminobu Tanizawa¹³, Toru Arai¹⁴, Takuya Kotani¹⁵, Motomu Hashimoto¹⁶, Shintaro Hirata⁷, Yoshiya Tanaka¹⁷, Tsuneyo Mimori¹⁸ and Akio Morinobu¹⁹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ³Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University, Osaka, Japan, ⁶Department of Clinical Immunology, Osaka Metropolitan Graduate School of Medicine, Osaka, Japan, ⁷Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ⁸Department of Molecular Targeted Therapies, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Department of Molecular Targeted Therapies (DMTT), University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁰Department of Advanced Medicine for Respiratory Failure and Graduate School of Medicine, Kyoto University, Kyoto, Japan, ¹¹Department of Respiratory Medicine, Kobe City Medical Center West Hospital, Kobe, Japan, ¹²Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan, ¹³Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan, ¹⁴Clinical Research Center, NHO Kinki-Chuo Chest Medical Center, Sakai, Japan, ¹⁵Division of Rheumatology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, Osaka, Japan, ¹⁶Osaka Metropolitan University, Osaka, Japan, ¹⁷University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁸Takeda Clinic for Rheumatic Diseases, Kyoto, Japan, ¹⁹Kyoto University, Kyoto, Kyoto, Japan
Background/Purpose: Melanoma differentiation-associated gene 5 (MDA5) is a cytoplasmic RNA sensor and activates the innate immune response. Autoantibodies against MDA5 are associated with rapidly progressive…
Abstract Number: 2477 • ACR Convergence 2025
Current treatment Strategies in Systemic Sclerosis- Interstitial Lung Disease Patients: Real-World Insights from the EUSTAR Cohort (CP138)
Corrado Campochiaro¹, Marie-Elise Truchetet², Madelon Vonk³, Giacomo De Luca⁴, Giovanna Cuomo⁵, Lidia P Ananieva⁶, Eric Hachulla⁷, Vanessa Smith⁸, Ana Maria Gheorghiu⁹, Radim Bečvář¹⁰, Patricia E. Carreira¹¹, Nicolas Hunzelmann¹², Daniel Furst¹³, Vera Ortiz-Santamaria¹⁴, Francesco Del Galdo¹⁵, Marco Matucci-Cerinic¹⁶ and Anna-Maria Hoffmann-Vold¹⁷, ¹IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ²Bordeaux University Hospital, Bordeaux, France, ³Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Italy, ⁵Department of Precision Medicine, University Hospital Luigi Vanvitelli, Naples, Italy, Naples, Italy, ⁶A Nasonova Institute of Rheumatology, Moscow, Russian Federation, Moscow, Russia, ⁷University of Lille, LILLE, France, ⁸Ghent University Hospital, Gent, Belgium, ⁹Spitalul Clinic Dr. Ion Cantacuzino, Bucharest, Romania, ¹⁰Department of Internal Medicine, Charles University,, Prague, Czech Republic, ¹¹Hospital Universitario ¹² de Octubre, Madrid, Spain, ¹²Department of Dermatology and Venereology, University Hospital Cologne, Cologne, Germany, ¹³Southern California Scleroderma and Rheumatology Center, Los Angeles, CA, ¹⁴HOSP. GENERAL DE GRANOLLERS, Barcelona, Spain, ¹⁵University of Leeds, Leeds, United Kingdom, ¹⁶University San Raffaele Milano, Milano, Milan, Italy, ¹⁷Oslo University Hospital, Oslo, Norway
Background/Purpose: The therapeutic landscape for systemic sclerosis- interstitial lung disease (SSc-ILD) has rapidly evolved over the past decade, with increasing adoption of immunosuppressive (IST) and…
Abstract Number: 2133 • ACR Convergence 2025
Examination of HLA-DRB1*15-linked Candidate Antigens in Still’s Disease with and without Lung Disease and Features of Drug Hypersensitivity
Dale Kobrin¹, Garrett Brown², Mariana Correia Marques¹, Carol Lake³, Michelle Millwood⁴, Lisa Workman⁵, Monica Lawrence⁵, Zuoming Deng⁶, Sanchita Das² and Michael Ombrello⁷, ¹Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD, ³NIH, GAITHERSBURG, MD, ⁴National Institutes of Health (NIH), Bethesda, MD, ⁵Division of Asthma, Allergy, and Immunology, University of Virginia School of Medicine, Charlottesville, VA, ⁶Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD
Background/Purpose: Lung disease in systemic juvenile idiopathic arthritis and adult-onset Still’s disease (Still’s-LD) is a severe manifestation that strongly associates with features of drug hypersensitivity…
Abstract Number: 1869 • ACR Convergence 2025
A miRNA signature consisting of high Let7i-5p, high miR-483-5p, low miR-223- 3p characterizes connective tissue diseases with interstitial lung disease
Olga Sanchez Pernaute¹, Mª Jesus Rodriguez-Nieto², Cristina Vadillo Font³, Maria asuncion Nieto³, Laura Cebrian⁴, Belen Lopez Muñiz⁵, Hilda Godoy Tundidor⁶, Rosalia Laporta⁷, Jesus Loarce Martos⁸, Juan A Rigual⁸, fredeswinda Romero-Bueno⁹, Irene Llorente Cubas¹⁰, Claudia Valenzuela¹⁰, Gema Bonilla¹¹, Luis Gomez Carrera¹², Rosario Garcia Vicuña¹³, Ana Jaureguizar⁸, Jose Luis Morell Hita⁸ and lydia Abasolo Alcazar¹⁴, ¹Clinica Universidad de Navarra, Madrid, Madrid, Spain, ²Fundacion Jimenez Diaz (IIS-HUFJD), Madrid, Spain, ³Hospital Clínico S Carlos, Madrid, Spain, ⁴Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain, ⁵Hospital Universitario Infanta Leonor, Madrid, Spain, ⁶Hospital Universitario puerta de hierro, Madrid, Spain, ⁷Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ⁸Hospital Ramón y Cajal, Madrid, Spain, ⁹University Hospital Fundación Jiménez Díaz"", Madrid, Spain, ¹⁰Hospital Universitario Princesa, Madrid, Spain, ¹¹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Hospital Universitario de la Princesa, Madrid, Spain, ¹⁴IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Patients with interstitial lung disease associated to a connective tissue disease (CTD-ILD) are a heterogeneous population both concerning mechanisms and trajectories. In an RNA…
Abstract Number: 1580 • ACR Convergence 2025
Lung vasculature quantification on computed tomography predicts new onset of interstitial lung disease in systemic sclerosis
Maria Iacovantuono¹, Nicholas landini², lisa Jungblut³, Gesa Sauer⁴, Rucsandra Dobrota⁵, Sinziana Muraru⁶, Muriel Elhai⁷, Carina Mihai⁸, Mike Becker⁹, Maria Sole Chimenti¹⁰, Thomas Frauenfelder³, Anna-Maria Hoffmann-Vold¹¹, Oliver Distler¹² and Cosimo Bruni¹³, ¹Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Spinete, Italy, ²Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Rueil Malmaison, France, ³Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, zurich, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, zurich, Switzerland, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁶University of Zurich, University Hospital Zurich, Zürich, Switzerland, ⁷University Hospital zurich, Zürich, Switzerland, ⁸University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁹Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ¹⁰Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy, Roma, Italy, ¹¹Oslo University Hospital, Oslo, Norway, ¹²Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is highly prevalent in systemic sclerosis (SSc) and a leading cause of mortality. Recent studies have identified clinical risk factors…
Abstract Number: 1321 • ACR Convergence 2025
Efficacy and safety of janus kinase inhibitors in diffuse interstitial lung disease in rheumatoid arthritis. Systematic review
Olga Compán¹, Marta Ibañez², Olga Martínez³, Carolina Cristina Chacón⁴, Ricardo López Pérez³, Borja Felices López³, Belén Miguel Ibáñez³, Laura Blanco⁴, Sergio Cimadevila Santiago³, Ana Isabel Turrión Nieves³, Manuel Cipriano Martin Martinez³, Cristina Hidalgo Calleja⁴, Carlos Montilla⁴ and Susana Gómez⁴, ¹Rheumatology Service, University Hospital of Salamanca, Carbajosa de la Sagrada, ³⁷¹⁹¹, Spain, ²Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ³Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ⁴Rheumatology Service, University Hospital of Salamanca, Salamanca, Castilla y Leon, Spain
Background/Purpose: Interstitial lung disease (ILD) is a relatively common serious extra-articular complication in rheumatoid arthritis (RA). Although there have been great advances, we do not…
Abstract Number: 1156 • ACR Convergence 2025
Incidence and Prevalence of Interstitial Pneumonia with Autoimmune Features in a Population-Based Cohort
elena Joerns¹, Sara Achenbach¹, Cynthia Crowson², eva carmona¹, Robert Vassallo³, John Joerns¹, Vanessa Kronzer³, John Davis³ and Elena myasoedova³, ¹Mayo Clinic, Rochester, ²Mayo Clinic, Stewartvillle, MN, ³Mayo Clinic, Rochester, MN
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a type of interstitial lung disease (ILD) with features of autoimmunity, yet patients do not fulfill criteria…
Abstract Number: 0729 • ACR Convergence 2025
ANCA-associated vasculitis – does the type matter?
Tamanna Vinodkumar Mohta¹ and Umeh Chukwuemeka², ¹Hemet Global Medical Center, Irvine, CA, ²Hemet Global Medical Center, Hemet
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis is a heterogeneous group of rare autoimmune disorders that cause inflammation of blood vessels with various manifestations. Our study…
Abstract Number: 2475 • ACR Convergence 2025
GERD Severity, Proton Pump Inhibitor Use, and Longitudinal Forced Vital Capacity in the CONQUER Registry
Carrie Richardson¹, Shervin Assassi², Flavia Castelino³, Lorinda Chung⁴, Luke Evnin⁵, Tracy Frech⁶, Jessica Gordon⁷, Faye Hant⁸, Laura Hummers⁹, Dinesh Khanna¹⁰, Kimberly Lakin⁷, Dorota Lebiedz-Odrobina¹¹, Yiming Luo¹², Ashima Makol¹³, Maureen Mayes¹⁴, Zsuzsanna McMahan¹⁵, Jerry Molitor¹⁶, Duncan Moore¹⁷, Nora Sandorfi¹⁸, Ami Shah⁹, Ankoor Shah¹⁹, Brian Skaug²⁰, Virginia Steen²¹, Elizabeth Volkmann²², Carleigh Zahn²³, John VanBuren¹¹ and Elana Bernstein²⁴, ¹Northwestern University, Chicago, IL, ²Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ³Massachusetts General Hospital, Boston, MA, ⁴Stanford University, Stanford, CA, ⁵Scleroderma Research Foundation, Brisbane, CA, ⁶Vanderbilt University Medical Center, Nashville, TN, ⁷Hospital for Special Surgery, New York, NY, ⁸Medical University of South Carolina, Charleston, SC, ⁹Johns Hopkins Rheumatology, Baltimore, MD, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹University of Utah, Salt Lake City, UT, ¹²Columbia University Irving Medical Center, New York, ¹³Mayo Clinic, Rochester, MN, ¹⁴UT Health Houston Division of Rheumatology, Houston, TX, ¹⁵UT Health Houston, Houston, TX, ¹⁶University of Minnesota, Minneapolis, MN, ¹⁷Northwestern University, Chicago, ¹⁸University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, ¹⁹Duke University, Durham, NC, ²⁰UTHealth Houston Division of Rheumatology, Houston, TX, ²¹Georgetown University School of Medicine, Washington, DC, ²²Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²³University of Michigan, Ann Arbor, ²⁴Columbia University Irving Medical Center, New York, NY
Background/Purpose: Gastroesophageal reflux disease may contribute to the progression of interstitial lung disease in systemic sclerosis (SSc). However, it is unclear whether reflux severity or…
Abstract Number: 2075 • ACR Convergence 2025
Ferritin trends differentiate anti-MDA5 Dermatomyositis from anti-Jo1 Antisynthetase Syndrome
Silvia Grazzini¹, Edoardo Conticini¹, Marco Fornaro², Chiara Rizzo³, Lidia La Barbera³, Maria Rosa Pellico⁴, Stefano Stano⁵, Florenzo Iannone⁶, Giuliana Guggino³, Nicoletta Del Papa⁴, Luca Cantarini⁷ and Bruno Frediani⁷, ¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy, Siena, Italy, ²Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari, Italy., Bari, Italy, ³Rheumatology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) University of Palermo, Palermo, Italy, ⁴ASST Pini-CTO, Clinical Rheumatology Unit, Milano, Italy, ⁵⁶. Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy, ⁶Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ⁷Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University Hospital of Siena, Siena, Italy, Siena, Italy
Background/Purpose: Serum ferritin (FERR) is a recognized marker of immune activation and a key laboratory feature of anti-MDA5 Dermatomyositis (DM). It has been increasingly studied…
Abstract Number: 1863 • ACR Convergence 2025
Bag3 in systemic sclerosis: possible therapeutic target and biomarker for pulmonary fibrosis
Claudia Iannone¹, Margot De Marco², Antonina Minniti³, Giuseppe Armentaro⁴, Antonia Falco², Angela D'Ardia², paola Manzo², Liberato Marzullo⁵, Anna Basile², Alessandra Rosati², Maria Caterina Turco², Roberto Caporali⁶ and Nicoletta Del Papa⁷, ¹University of Milan, Gaetano Pini CTO, Milano, Milan, Italy, ²Department of Medicine, Surgery and Dentistry "Schola Medica Salernitana", University of Salerno, Baronissi, Italy, Baronissi, Campania, Italy, ³ASST Gaetano Pini, milano, Milan, Italy, ⁴ASST Pini-CTO, Clinical Rheumatology Unit, Milano, Italy, ⁵Department of Medicine, Surgery and Dentistry "Schola Medica Salernitana", University of Salerno, Baronissi, Italy, Baronissi, Italy, ⁶University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, ⁷ASST Pini CTO, Milano, Milan, Italy
Background/Purpose: BAG3 (Bcl2-associated athanogene 3) regulates cellular pathways including apoptosis and autophagy, and induces fibroblast-to-myofibroblast transformation. In systemic sclerosis (SSc), myofibroblasts drive fibrosis of skin…
Abstract Number: 1579 • ACR Convergence 2025
Exploring the Pulmonary Vascular Changes on Computed Tomography in predicting progression and mortality of Systemic Sclerosis-associated Interstitial Lung Disease
Maria Iacovantuono¹, Nicholas landini², lisa Jungblut³, Florian Käs⁴, Rucsandra Dobrota⁵, Sinziana Muraru⁶, Carina Mihai⁷, Muriel Elhai⁸, Mike Becker⁹, Maria Sole Chimenti¹⁰, Thomas Frauenfelder³, Anna-Maria Hoffmann-Vold¹¹, Oliver Distler¹² and Cosimo Bruni¹³, ¹Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Spinete, Italy, ²Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Rueil Malmaison, France, ³Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, zurich, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁶University of Zurich, University Hospital Zurich, Zürich, Switzerland, ⁷University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Schlieren, Switzerland, ⁹Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ¹⁰Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy, Roma, Italy, ¹¹Oslo University Hospital, Oslo, Norway, ¹²Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is the main cause of mortality in systemic sclerosis (SSc). Among radiomics features, the automated quantification of pulmonary vascular volume…
Abstract Number: 1308 • ACR Convergence 2025
Predictors of Interstitial Lung Disease Progression in Patients with Rheumatoid Arthritis
Bryant England¹, Austin Wheeler¹, Halie Frideres², Scott Matson³, Geoffrey Thiele¹, Katherine Wysham⁴, Grant Cannon⁵, Gary Kunkel⁶, Gail Kerr⁷, Andreas Reimold⁸, John Richards⁹, Dana Ascherman¹⁰, Paul Monach¹¹, Joshua Baker¹² and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC Department of Rheumatology, Omaha, NE, ³University of Kansas, Kansas City, MO, ⁴VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁶University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁷Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁸Dallas VA Medical Center, Dallas, TX, ⁹Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹⁰University of Pittsburgh, Pittsburgh, PA, ¹¹VA Boston Healthcare System, Boston, MA, ¹²University of Pennsylvania, Philadelphia, PA
Background/Purpose: Interstitial lung disease (ILD) is a frequent extra-articular manifestation of RA predisposing to poor health outcomes. The disease course in RA-ILD is variable, with…

« Previous Page
1
…
3
4
5
6
7
…
47
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].